Results 1 to 10 of about 26,897 (178)
Efficacy and Safety of Moxidectin, Synriam, Synriam-Praziquantel versus Praziquantel against Schistosoma haematobium and S. mansoni Infections: A Randomized, Exploratory Phase 2 Trial. [PDF]
PLoS Neglected Tropical Diseases, 2016 BACKGROUND:Schistosomiasis affects millions of people, yet treatment options are limited. The antimalarial Synriam (piperaquine 150 mg/arterolane 750 mg) and the anthelminthic moxidectin revealed promising antischistosomal properties in preclinical or ...
Beatrice Barda +5 more
doaj +61 more sources
Optimal single sampling time-point for monitoring of praziquantel exposure in children
Scientific Reports, 2021 Praziquantel pharmacokinetics studies in schistosomiasis infected children are scarce partly due to the challenges/complexity of intensive blood sampling in the target population. This study was aimed to investigate the optimal single sampling time-point
Rajabu Hussein Mnkugwe +5 more
doaj +1 more source
Chromatographic Quantification of Ivermectin and Pranziquantel in the Tablets Using Stability Indicating RP-HPLC Method [PDF]
Pharmaceutical Sciences, 2019 Background: A new stability indicating RP-HPLC based assay method was developed to quantify ivermectin and praziquantel simultaneously and applied effectively to tablets.
Naga Venkata Suresh Kumar Devaka +1 more
doaj +1 more source
Uptake of preventive treatment for intestinal schistosomiasis among school children in Jinja district, Uganda: a cross sectional study. [PDF]
PLoS ONE, 2013 BACKGROUND: In Uganda, the current national health sector strategic and investment plan underscores schistosomiasis as one of the diseases targeted for elimination by the year 2015.
Simon Muhumuza +3 more
doaj +1 more source
Potential cost-effectiveness of schistosomiasis treatment for reducing HIV transmission in Africa--the case of Zimbabwean women. [PDF]
PLoS Neglected Tropical Diseases, 2013 Epidemiological data from Zimbabwe suggests that genital infection with Schistosoma haematobium may increase the risk of HIV infection in young women. Therefore, the treatment of Schistosoma haematobium with praziquantel could be a potential strategy for
Martial L Ndeffo Mbah +6 more
doaj +1 more source
Pharmaceutics, 2023 To date, the treatment for cysticercosis and neurocysticercosis consists of a single oral intake of praziquantel (5–10 mg/kg), which since it is only available as tablets, hinders its administration to pediatric patients.
Giselle Bedogni +4 more
doaj +1 more source
Brazilian Journal of Pharmaceutical Sciences, 2010 The solubility behavior of drugs remains one of the most challenging aspects in formulation development. Solid Dispersion (SD) has tremendous potential for improving drug solubility.
Marco Vinicius Chaud +5 more
doaj +1 more source
Aktualʹnì Pitannâ Farmacevtičnoï ì Medičnoï Nauki ta Praktiki, 2016 Acne dermatoses (rosacea, perioral dermatitis, seborrheic dermatitis etc.) are one of the most actual problems in dermatology. Praziquantel is an antiparasitic medication effective towards trematodes, cestodes.
D. M. Romanina +2 more
doaj +1 more source
Parasites & Vectors, 2020 Background The control of schistosomiasis has been centered to date on a single drug, praziquantel, with shortcomings including treatment failure, reinfection, and emergence of drug resistance. Drug repurposing, combination therapy or nanotechnology were
Maha M. Eissa +5 more
doaj +1 more source
Tropical Medicine and Infectious Disease, 2018 The World Health Organization (WHO) recommends praziquantel mass drug administration (MDA) to control schistosomiasis in endemic regions. We aimed to quantify recent and lifetime praziquantel coverage, and reasons for non-treatment, at an individual ...
Moses Adriko +5 more
doaj +1 more source